Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment With Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab
Lenacapavir, teropavimab, and zinlirvimab maintained a high rate of virologic suppression through W26, with rare emergent lenacapavir resistance and no bNAb resistance, supporting further Phase 2 evaluation.
Authors
- Lisa Selzer
- Joseph J. Eron (ORCID: https://orcid.org/0000-0002-4938-0644)
- Brie Falkard (ORCID: https://orcid.org/0009-0006-8599-8173)
- Sally Demirdjian (ORCID: https://orcid.org/0000-0003-0659-0614)
- Laurie A. VanderVeen
- Ross Martin (ORCID: https://orcid.org/0000-0003-2105-4748)
- Christian Callebaut (ORCID: https://orcid.org/0000-0003-4721-2572)
- Sean E Collins (ORCID: https://orcid.org/0009-0002-9657-6874)
- Jiani Li (ORCID: https://orcid.org/0009-0002-5563-4505)
Institutions
- University of North Carolina at Chapel Hill (US)
- Gilead Sciences (United States) (US)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1093/infdis/jiaf559
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences